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Integrated human/SARS-CoV-2 metabolic models present
novel treatment strategies against COVID-19
Bridget P Bannerman1,5 , Jorge Júlvez3 , Alexandru Oarga3 , Tom L Blundell2, Pablo Moreno4, R Andres Floto1
The coronavirus disease 2019 (COVID-19) pandemic caused by the new
coronavirus (SARS-CoV-2) is currently responsible for more than 3
milliondeaths in219countriesacross theworldandwithmore than140
million cases. The absence of FDA-approved drugs against SARS-CoV-2
has highlighted an urgent need to design new drugs. We developed an
integratedmodel of the human cell and SARS-CoV-2 to provide insight
into the virus’ pathogenic mechanism and support current therapeutic
strategies. We show the biochemical reactions required for the growth
and general maintenance of the human cell, first, in its healthy state.
We thendemonstrate how the entry of SARS-CoV-2 into the human cell
causes biochemical and structural changes, leading to a change of cell
functions or cell death. A new computational method that predicts 20
unique reactions as drug targets from our models and provides a
platform for future studieson viral entry inhibition, immune regulation,
and drug optimisation strategies. The model is available in BioModels
(https://www.ebi.ac.uk/biomodels/MODEL2007210001) and the soft-
ware tool, findCPcli, that implements the computational method is
available at https://github.com/findCP/findCPcli.
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Introduction
SARS-COV-2, the causativeagentof COVID-19, belongs toagroupof viruses
commonly knownasβ-coronavirus. This class of viruses is responsible for
mild-to-fatal respiratory tract infections in animals andbirds.Whereas the
common cold is more commonly associated with the mild forms of the
disease, the previous MERS and SARS-2002 infections and, currently,
COVID-19 belong to the group of fatal diseases. The genome of the virus
responsible for the ongoing COVID-19 disease, SARS-CoV-2, has ~80%
sequence identity to SARS-CoV and is 96% identical at the whole-genome
level to a bat coronavirus (Zhou et al, 2020). SARS-CoV-2 affects the lower
respiratory tract cells and the upper cells in the pharyngeal region (Chen
et al, 2020; Huang et al, 2020), and the viral infections range from
asymptomatic, mild, moderate, and severe cases. Previous studies in
China show that 86% of cases of infection and the contagiousness
of the virus were undocumented before travel restrictions were
imposed (Li et al, 2020). In addition, the interim results from the
Solidarity international clinical trial conducted by the World Health
Organization confirmed that only corticosteroids are effective against
severe and critical cases of COVID-19. The report shows little or no
benefit from the other four treatments evaluated (remdesivir, hydrox-
ychloroquine, lopinavir/ritonavir, and interferon) on overall mortality
against COVID-19 (Dyer, 2020; Pan et al, 2021). Therefore, there are
still many factors to unravel regarding the stages of infection and
transmissibility patterns of the virus to achieve good treatment man-
agement strategies. Studies in France demonstrate the transmission
potential of asymptomatic persons and suggest varying dynamics of
transmission in children (Danis et al, 2020). The human angiotensin-
converting enzyme 2 (human-ACE-2 protein) has been identified as the
cell receptor for both the SARS-2002 virus and SARS-CoV-2. The ACE-2
enzyme, which has the primary function of controlling blood pressure,
is usually found in the epithelial cells of the heart, lungs, kidneys, and
intestine (Donoghue et al, 2000; Hamming et al, 2004; Liu et al, 2020).
The mechanism of replication of SARS-CoV-2 in the human cell
involves an initial binding and attachment of the spike (S) glyco-
protein to the angiotensin-converting enzyme 2 (ACE2) receptor of
its host. During endocytosis, the virus’s genetic material is injected
into the host cell, where it loses its protective envelope (Fig 1). The
subsequent assembly and maturation of viral proteins lead to cell
death and proliferation of the virus within the human body.
The lack of FDA-approved drugs against COVID-19, coupled with the
difficulties encountered globally in containing the virus, prompted the
WHO to declare the outbreak a pandemic in March 2020. This has led to
intensified efforts around theworld tofight this disease. Previous studies
in drug target identification against viral diseases such as Zika, chi-
kungunya, and dengue by Aller et al, (2018) introduced a system of in-
tegrating the host’s macrophage and viral metabolic networks to predict
a set of host reactions which, when constrained, can inhibit viral pro-
duction. A recent study by Renz et al, (2020) demonstrates a similar
approachandpredicts drug targets against SARS-CoV-2. Targets of known
antiviral drugs predicted from both studies, using a macrophage met-
abolic model (Bordbar et al, 2010) demonstrate the applicability of the
integrated human/virus metabolic modelling in drug target identifica-
tion. The alveolar macrophage host model (Bordbar et al, 2010) used to
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illustrate the metabolic interactions between multiple organisms was
constructed from the Homo sapiens Recon 1 model (Duarte et al, 2007)
basedonpreviously built algorithms. Thiswas followedby a set ofmanual
curation processes to construct the context-specific alveolar macrophage
host model (Bordbar et al, 2010). Similarly, Wang et al (2012) developed
several draft context-specific models using the Human Recon 1 model.
We have built on these approaches by developing an integrated
epithelial cell/SARS-CoV-2 metabolic model and used a combination of
structural and dynamical analyses to assess the model and make
predictions.We have applied the recently released community standards
to facilitate our development of a standardised model for the systems
biology international community and used the MEMOTE quality control
software to assess and compare our model with previously developed
GEMS (Carey et al, 2020, Lieven et al, 2020). We have designed a novel
computationalmethod anddeveloped a software tool (findCPcli) to carry
out such analyses and to predict drug targets. Both the model and the
tool have been uploaded to public repositories (see the Data Availability
section). We have also performed a comparative analysis of our model
and other previously generated cell-type models.
Results
Construction of the human airway epithelial cell and the
SARS-CoV-2 virus
We constructed an integrated genome-scale metabolic model (GEM)
of the human airway epithelial cell with the SARS-CoV-2 virus using
the methods described in Aller et al (2018) and Renz et al (2020). We
used a previous draft reconstruction of the epithelial cell (Wang
et al, 2012) and improved on the context-specificity of the GEM with
the addition and simulation of data from the gene expression omnibus
on COBRApy (Ebrahim et al, 2013). We performed further refinement
from literature and by using the human metabolic networks in the
HumanCyc database (Trupp et al, 2010) andRecon3D (Brunk et al, 2018).
Model checks were done with MEMOTE, and refinements were per-
formed with MetaNetX 4.2, BiGG, ChEBI, MetaCyc, and PubChem da-
tabases (Caspi et al, 2014; Hastings et al, 2016; Norsigian et al, 2020;
Kim et al, 2021; Moretti et al, 2021). The new GEM contains 4,660 genes,
3,614 reactions, and 4,052 metabolites and conforms to the minimum
standardised content for a newly published GEM based on recently
published community standards (Carey et al, 2020); 100% of the me-
tabolites in (iHsaEC21) have a human-readable descriptive name, 100%
have an inchi key, 100% of metabolite annotation conformity with the
BiGG database and in MetaNetX, Kyoto Encyclopedia of Genes and
Genomes (KEGG), ChEBI, ModelSEED, HMDb, or MetaCyc (Caspi et al,
2014; Hastings et al, 2016; Wishart et al, 2018; Norsigian et al, 2020;
Kanehisa et al, 2021; Kim et al, 2021; Moretti et al, 2021; Seaver et al,
2021); 100% of the metabolites have a charge and chemical formula
with a charge balance of 75.3% (Supplemental Data 1). In addition,
97% of the reactions have a human-readable descriptive name, 100%
of reactions conform with the BiGG database and as well as in
MetaNetX, KEGG, ChEBI, ModelSEED, HMDb, or MetaCyc. The Gene IDs
in the model are consistent with gene annotations in Uniprot with
92.5% of reactions having Gene-Protein-Reaction associations and
71.9% having the Enzyme Classification code.
Figure 1. The mechanism of replication of SARS-CoV-2 in the human cell.
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Comparative analysis of integrated models of infected human
epithelial cell and the macrophage cell with SARS-CoV-2
For our study, we performed a comparative analysis of the essential
and unique reactions needed for the viability of the virus in the ep-
ithelial cell/SARS-CoV-2 integratedmodel and the GEM constructed by
Renz et al (2020). Our results showhow the virus heightens its virulence
mechanisms by modifying the host’s defences within different cell
compartments. Consequently, we suggest treatment regimens based
on different stages of viral infection and replication.
Host-dependent metabolic pathways
We initially demonstrated the biochemical requirements for the
maintenance of the human airway epithelial and macrophage cells
and used the integrated models to show the essential host reactions
needed for the survival and viability of SARS-CoV-2 within the host’s cell
compartments. We have mapped the experimentally characterized
human/SARS-CoV-2 protein–protein interaction data fromGordon et al
(2020) on the in silico virus-integrated human macrophage and epi-
thelial cells. Of the 334 metabolic pathways in the human metabolic
network, 48 pathways including the biosynthesis and degradation
pathways of amino acids, fatty acids, carbohydrates, amines, cofactors,
and core components of the central mRNAmetabolism are hijacked by
the virus for its survival strategies (Fig 2).
The 48 metabolic pathways that were mapped to the protein–
protein interaction network produced by Gordon et al (2020) are
referred to as PPi-pathway intersection nodes in this article (Table 1).
These include cysteine, methionine, and selenocysteine amino
acid biosynthetic pathways; C20 prostanoid hormone biosyn-
thetic pathways; and vitamin D3 and vitamin K epoxide cycle. The
degradation pathways identified include the lysine, tryptophan,
methionine, fatty acid degradation, ceramide, and sphingolipid
recycling pathways; phospholipases degradation; and amine and
heme degradation (Table 1).
Our results identify host dependency factors required for the
SARS-CoV-2 virus infection, replication, survival, and viability within
different cell compartments and provide insight into novel treat-
ment strategies.
Essential reactions for the host and viral metabolism
The Flux Balance Analysis (FBA) method (Orth et al, 2010) was used
to compute both the biomass maintenance of the cell in the ab-
sence of virus and the maximum growth rate of the virus in the cell
(host optimum and virus optimum conditions). We identified 52
essential reactions in the macrophage (iAB-AMØ-1410) model and
10 reactions in the epithelial cell model (iHsaEC21) essential for the
virus to propagate (Tables S1 and S2). It was also demonstrated that:
(i) the maximal biomass maintenance of the macrophage cell in the
absence of virus was 0.0269 (Table S1) and 0.012 h−1 for the human
airway epithelial cell (Table S2); (ii) the maximum growth rate of the
virus in the macrophage cell was 0.0144 and 0.0181 h−1 in the human
airway epithelial cell. These numerical results mean that 0.0144 h−1
is the theoretical maximum of the growth rate of the virus in the
human macrophage cell. If this flux is assigned to the viral growth
Figure 2. SARS-CoV-2 viral genome and host-dependent metabolic pathways.
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reaction, then flux variability analysis (FVA) (Orth et al, 2010) can be
used to calculate the ranges of fluxes allowed for the remaining
reactions in the cell while the virus is being replicated at its op-
timum condition. The execution of FVA under such conditions
produced zero biomass maintenance of the host cell, that is, both
the lower and upper flux bounds of the reaction indicate that the
growth is zero. This means that if the virus is replicating at its
maximum rate, then the cell will not be viable.
Bottleneck reactions and the prioritization of potential drug
targets
The bottleneck reactions identified by the findCPcli tool are unique
reactions of the metabolic network required for the growth and
survival of the organism and, like chokepoint reactions, are po-
tential drug targets (Yeh et al, 2004; Oarga et al, 2020). Although
classical chokepoint reactions identify reactions that are the only
Table 1. List of bottleneck and essential enzymes on the PPi-pathway intersection nodes.
Class Pathway Sub-pathway Humangene Sars gene Macrophage
Epithelial
cell
Biosynthesis Amino acids L-selenocysteine biosynthesis SEPSECS Nsp8 Y N
Biosynthesis Amino acids Cysteine, and methionine MAT2B Nsp9 Y Y
Biosynthesis Fatty acids Fatty acid and long fatty acid biosynthesis SLC27A2 Nsp2 Y Y
Biosynthesis Fatty acids Fatty acid and long fatty acid biosynthesis ACSL3 Nsp7 Y N
Biosynthesis Fatty acids Stearate biosynthesis SLC27A2 Nsp2 Y Y
Biosynthesis Fatty acids Stearate biosynthesis ACSL3 Nsp7 Y Y
Biosynthesis Carbohydratebiosynthesis Glycan and oligosaccharide biosynthesis ALG11 Nsp4 Y Y
Biosynthesis Carbohydratebiosynthesis Glycan HS2ST1 Orf8a Y Y
Biosynthesis Carbohydratebiosynthesis Glycan MOGS Nsp7 Y Y
Biosynthesis Carbohydratebiosynthesis Glycan and oligosaccharide biosynthesis ALG5 ORF3a Y Y
Biosynthesis Carbohydratebiosynthesis
Glycan, oligosaccharide, and glycosaminoglycan
biosynthesis CHPF ORF8a Y Y
Biosynthesis Carbohydratebiosynthesis
Glycan, oligosaccharide, and glycosaminoglycan
biosynthesis HS6ST2 ORF8a Y Y
Biosynthesis Cofactors Vitamin D3 biosynthesis POR Nsp2 Y Y
Biosynthesis Cofactors Vitamin K epoxide cycle GGCX Mainprotease N Y
Biosynthesis Hormones C20 prostanoid biosynthesis PTGES2 Nsp7 Y Y
Biosynthesis tRNA charging tRNA charging TARS2 Mainprotease Y Y
Degradation Amino acids L-lysine degradation AASS Mainprotease N Y
Degradation Amino acids L-tryptophan degradation POR Nsp2 Y Y
Degradation Amino acids L-methionine degradation MAT2B Mainprotease Y Y
Degradation Fatty acids Ceramide and sphingolipid recycling SLC27A2 Nsp2 Y Y
Degradation Fatty acids Ceramide and sphingolipid recycling POR Nsp2 Y Y
Degradation Fatty acids Ceramide and sphingolipid recycling ACSL3 Nsp7 Y Y
Degradation Fatty acids Phospholipases PLD3 ORF8a Y Y
Degradation Amine degradation Dopamine degradation COMT Nsp7 Y Y
Degradation Hormones Heme HMOX1 ORF3a Y Y
Degradation Hormones melatonin POR Nsp2 Y Y
Degradation Hormones Adrenalin COMT Nsp2 Y Y
Degradation Hormones L-dopa degradation COMT Nsp2 Y Y
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producers or the only consumers of a given metabolite and con-
sider just the model structure, we improve on this approach by
using both the structural and dynamical information. FVA is used to
compute flux bounds of the reactions, and in turn, to determine
whether a given reaction is reversible or not. Reversibility will be
used to obtain the sets of metabolites that can be produced and
consumed by the reactions, and thus, to compute flux-dependent
bottleneck reactions. This approach has been applied to the in-
tegrated Human/SARS-CoV-2 metabolic model within the airway
epithelial cell and the macrophage cell to predict potential drug
targets against SARS-CoV-2.
We initially identified 1,595 bottleneck reactions required for the
virus’ maintenance and replication in the human macrophage cell;
these include pathways in lipidmetabolism, coenzyme transport and
metabolism, energy production and conversion, and amino acid and
nucleotide transport andmetabolism (Table S3). In the humanairway
epithelial cell, 1,598 bottleneck reactions were initially identified;
these include the biosynthesis and degradation pathways of amino
acids, fatty acids, carbohydrates, amines, cofactors, and some compo-
nents of the central mRNA metabolism (Table S4).
Because each bottleneck reaction should be balanced by at least
one other reaction that produces or consumes that metabolite, we
have excluded reactions in the model with dead-end metabolites.
The bottleneck reactions are potential drug targets as they are
indispensable for the maintenance and replication of the virus
within the host. To rank the potential drug targets identified, we
prioritised enzymes for unique reactions that occur at the nodes of
intersection between the bottleneck and essential reactions and
the results from the human/virus protein–protein interaction
network (Gordon et al, 2020) (Table 1). The following steps were
taken to label the reactions which occur at the nodes of inter-
sections between the referenced points above: (1) we initially
identified both the bottleneck and essential reactions to the virus
within the model, (2) we highlighted the interactions between the
viral proteins and the human metabolic enzymes, and (3) we se-
lected the reactions from the human/virus interactions which are
also present in the list of bottleneck and/or essential reactions.
The enzymes of the reactions at the nodes of intersection are (1)
host dependency factors identified by the model as necessary for
the survival of the virus and (2) proteins from experimental datasets
with high-confidence virus–human protein–protein interaction data;
we refer to these points of intersection as PPi-pathway inter-
section nodes.
The PPi-pathway intersection (P-Pi) nodes identified are present
in biosynthesis pathways such as the cysteine and S-adenosyl-L-
methionine biosynthetic pathways. In both pathways, the enzyme
S-adenosylmethionine synthase (MAT2B) catalyses the phosphor-
ylation reaction of methionine to S-adenosyl-L-methionine. During
infection, the viral protein Nsp9 is seen to react withMAT2B (Gordon
et al, 2020) (Fig 3A–C). Another viral protein, Nsp8, also interacts with
the enzyme O-phosphoseryl-tRNA(Sec) selenium transferase (SEPSECS),
which catalyses the last step of the L-selenocysteine biosynthesis
pathway (Fig 4).
P-Pi nodes also occur in a network of various fatty acid and
stearate biosynthetic pathways with Nsp2 interacting with the very
long-chain acyl-CoA synthetase (SLC27A2) (Fig 5A and B). The viral
protein, Nsp2, also interacts with POR in other pathways including
vitamin D3 biosynthesis (Fig 5C) and in L-tryptophan degradation,
ceramide, and sphingolipid recycling pathways (Table 1).
In carbohydrate metabolism, a P-Pi node is identified at the
glycan and oligosaccharide biosynthetic pathways, and specifically
where two mannose residues are added in α (1→2) linkages to the
nascent oligosaccharide and catalysed by the enzyme ALG11. The
viral protein Nsp4 interacts with ALG11 during the infection of the
SARS-CoV-2 virus (Fig 6). Another viral protein, Nsp7, interacts with
ACSL3 in the γ-linolenate biosynthesis (Fig 7A). Nsp7 also reacts with
ACSL3 and ORF8a interacts with HS2ST1 (Fig 7B), a key enzyme in-
volved in the heparan sulfate biosynthesis pathway. The first enzyme
of the N-linked oligosaccharide processing pathway, mannosyl-
oligosaccharide α-1,2-glucosidase (MOGS), also interacts with Nsp7
and ORF8a (Fig 7C).
P-Pi nodes specific to the human macrophage cell include the
O-phosphoseryl-tRNA(Sec) selenium transferase in the L-seleno-
cysteine biosynthetic pathway, which interacts with the viral pro-
tein Nsp8. The alkylglycerone-phosphate synthase/Nps7 P-Pi node,
which is present in the phospholipid/plasmalogen biosynthetic
pathway is also specific to the macrophage cell. Alternatively,
PPi-pathway intersection nodes common to both human airway
epithelial cell and the macrophage cell include the MAT2B/Nsp9
intersection pathways present in the cysteine metabolism and
L-methionine degradation. P-Pi nodes specific to the human epi-
thelial cell include the peptidyl-glutamate 4-carboxylase present in
the Vitamin K epoxide cycle and the α-aminoadipic semialdehyde
synthase enzyme in the L-lysine degradation pathway.
Discussion
Metabolic pathway perturbations in the human cell due to COVID-19
reflect the viral entry and infection of SARS-CoV-2 and the immune
regulation changes in the human body. We have used in silico
models to study the interactions of SARS-CoV-2 in the host and
propose new treatment management regimens. We have built on
studies using the human alveolar macrophage model iAB-AMØ-1410
(Bordbar et al, 2010) as host cells and SARS-CoV-2 (Renz et al, 2020,
2021); influenza ((Aller et al 2018)), and tuberculosis as pathogens and
developed a new integrated model of the human epithelial cell and
SARS-CoV-2.
The initial draft epithelial cell model was based on the human
Recon1 model and consists of 1,206 reactions, 994 metabolites, and
0 genes (Wang et al, 2012). Our revised iHsaEC21 epithelial cell
model contains 4,660 genes, 3,614 reactions, and 4,052 metabolites
initially scored 34% on MEMOTE (Lieven et al, 2020). After further
refinements using Recon3D, HumanCyc, MetaNetX 4.2, BiGG, ChEBI,
MetaCyc, and PubChem databases (Caspi et al, 2014; Hastings et al,
2016; Norsigian et al, 2020; Moretti et al, 2021) including manual
curations with literature, iHsaEC21 now has a MEMOTE quality score
of 51% (Supplemental Data 1). Although the iAB-AMØ-1410 (Bordbar
et al, 2010) was also developed from the human Recon1 model,
there was further refinement with literature, which attributed to its
quality score of 45% (Supplemental Data 2) compared with the draft
epithelial cell model fromWang et al (2012) which had a low-quality
score of 19% (Supplemental Data 3).
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Previous studies have also demonstrated the role of the ACE2 as
the receptor for both the SARS-CoV and the SARS-CoV-2. The ACE2
cells are expressed in the human airway epithelial cells (Hamming
et al, 2004; Liu et al, 2020). In this study, we have constructed an
integrated human epithelial cell and SARS-CoV-2 to provide insight
into the infection patterns of the virus in the human body.
Our in silico comparative analyses of the SARS-CoV-2 viral in-
fection between two different conditions (infected human macro-
phage and airway epithelial cells) show the requirements of viability
of the virus between these two conditions. Our results complement
previous efforts to propose drug targets and repurposing strategies
including the SARS-CoV-2-Human Protein–Protein Interaction Map
Gordon et al, (2020 and studies from Steward, 2020, which identified
host dependency factors facilitating virus infection. We also provide
additional resources to the COVID-19 disease map (Ostaszewski et al,
2020). In addition, we have designed a new algorithm (Oarga et al,
2020) and used the dynamic information of the human/virus models
to predict new treatment regimens. Here, we demonstrate the flux
changes from lipid metabolism, cofactor biosynthetic pathways, re-
dox balance, and immune regulation indicative of pathogenic reac-
tions arising from the COVID-19 viral infections.
Inhibition of viral entry and replication
The components of the plasma membrane, such as cholesterol and
sphingolipid-rich lipid, Abu-Farha et al, (2020) are involved in virus
penetration, entry, replication, and infection (Wang et al, 2008; Abu-
Farha et al, 2020). In this study, we demonstrate current therapeutic
strategies that interfere with different stages of the viral cycle by
targeting lipidmetabolism and proposing new treatment strategies.
The dynamical changes of flux metabolism in our in-silico virus
optimal models show a significant increase in viral infection. Four
reactions involved in the biosynthesis of fatty acids with predicted
non-zero fluxes in the host model exhibit an average increase of
190% in their maximum fluxes in the viral model (the maximumFigure 4. PPi-pathway intersection node—Nsp8.
Figure 3. PPi-pathway intersection node—Nsp9.
(A) Methionine degradation. (B) Methionine salvage cycle. (C) Cysteine biosynthesis.
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increase is 298%). The average increase of 32 reactions in lipid
metabolism with non-zero fluxes in the host model is 277% (the
maximum increase is 498%). Concerning sphingolipid metabolism,
14 of 15 reactions with non-zero fluxes in the host model exhibit an
average increase of 228% (the maximum increase is 298%) and
similar increases in phospholipases and palmitic acid biosynthesis
(Fig 5A and B). We show an average increase of 190% in cholesterol
and fatty acid metabolism during viral infection and demonstrate
the essentiality of these pathways to SARS-CoV-2. Previous studies
have shown that cholesterol and fatty acids are main components
of the viral membranes and needed for viral replication (Heaton &
Randall, 2011); therefore, drugs inhibiting these pathways such as
AM580, statins, and fibrate (Fiévet & Staels, 2009) will be essential
for both early and late stages of COVID-19.
Sphingolipids are composed of both hydrophobic and hydro-
philic units and play a large role in the endocytic or exocytic viral
entry processes into the cell (Dimitrov, 2004). The pH-dependent
endocytic process is further enhanced by the presence of clathrin, a
protein present in the plasma membrane, the Golgi apparatus and
in the cytoplasm, whereas the exocytic route involves viral crossing
through the plasma membrane at neutral pH. Our results show a
threefold increase in sphingolipid metabolism during viral infec-
tion (Fig 5); we hypothesise that drugs inhibiting sphingolipid
metabolism and/or the endocytosis process will inhibit infection of
SARS-CoV-2. Indeed, a sphingosine kinase-2 (SphK2) inhibitor,
opaganib, which has proved beneficial in the treatment of COVID-19,
is currently in global phase 2/3 clinical trials and in US phase 2
studies. Previous studies also demonstrate that chloroquine and
hydroxychloroquine elevate the pH of endosomes in the cells and
directly inhibit endocytosis and the exocytic process (Munro et al, 1997;
Devaux et al, 2020). More recent studies have also shown that
artemisinin-inhibited endocytosis (Hoppe et al, 2004; Uzun & Toptas,
2020). A recent study by Abu-Farha described other lipid-modifying
drugs including LJ-001, arbidol, methyl-B-cyclodextrin (Blaising et al,
2013; de Wilde et al, 2014; Mazzon & Marsh, 2019). We highlight critical
reactions as drug targets for lipid metabolism for the SARS-CoV-2 virus
(Table S2) and in our PPi-pathway intersection nodes (Table 1).
Our lists of bottleneck, essential reactions, and PPi-pathway
intersection nodes also include critical points in the biosynthe-
sis of phospholipids. We show that these reactions are essential for
viral infection and replication (Table 1) and propose targeting the
phospholipase enzyme or the interacting Nsp2 protein to inhibit
viral replication. Our results support previous studies from Müller
et al (2018) that targeting the phospholipase enzyme could inhibit
the early stage of COVID-19.
Redox homeostasis and antioxidant therapy
Redox homeostasis refers to the ability of the cell to maintain its
balance amidst infections and other unstable cellular environmental
factors. Delgado-Roche and Mesta (2020) have described oxidative
stress as a key player in severe acute respiratory syndrome coronavirus
(SARS-CoV) infection with cytokine production. Foyer and Noctor (2005)
have previously shown that antioxidants, such as glutathione and
Figure 5. PPi-pathway intersection node—Nsp2.
(A) Fatty acid oxidation. (B) Stearate biosynthesis. (C) Vitamin D3 biosynthesis.
Integrated human/SARS-CoV-2 metabolic model Bannerman et al. https://doi.org/10.26508/lsa.202000954 vol 4 | no 10 | e202000954 7 of 13
ascorbate, are important metabolites for the cellular redox state. Our
studieshave identifiedkey target enzymes involved in themetabolismof
glutathione and ascorbic acid as bottleneck and essential reactions,
including glutathione synthase, glutathione peroxidase, and ascorbic
acid oxidase (Table S2). We also demonstrate an increase in the flux of
these enzymatic reactions on infection of the virus. In a recent study,
Horowitz et al (2020) previously demonstrated how the use of high dose
oral and/or IV glutathione on severe outcomes of SARS-CoV-2 led to
favourable treatment outcomes. Other studies have shown that steroids
such as dexamethasone and Methylprednisolone are used to treat
severe cases of COVID-19. Because of the possible side effects of steroid
treatment, wepropose theuseof glutathioneas therapy for severe cases
Figure 6. PPi-pathway intersection node—Nsp4.
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of COVID-19 in the aged population and other severe caseswith cytokine
storm syndrome.
Immune regulation
SARS-CoV-2 can proliferate unhindered in infected cells because of the
lack of immunity in humans (Felsenstein et al, 2020). The result is cell
death, a release of viral particles to the extracellular environment and a
general hyperactivity of the immune system in some patients with severe
COVID-19 disease and subsequent lung inflammation and cytokine
syndrome. Immunocompromised patients or those with underlying
symptoms such as diabetes, hypertension, and transplantation aremost
affected (Zhonget al, 2020). Although clinical trials are ongoingworldwide
with various antivirals and immune-modulating treatments, there is
currently limited knowledge on the host dependency factors responsible
for the individual outcomes of the disease. Our results provide insight
into the immune evasion strategies of the SARS-CoV-2 virus; we dem-
onstrate changes in the flux metabolism of vitamin D and tryptophan
metabolismduring viral infection. Vitamin D is important for bone growth
and turnover and a low vitamin D status is associated with increased
susceptibility to upper respiratory tract infections (Mitchell, 2020). Pre-
vious studies have shown that supplementation of vitamin D prevents
acute respiratory tract infections (Martineau et al, 2017). Our results
highlight vitamin D as an essential reaction in the PPi-pathway inter-
section nodes and we show the viral protein Nsp2 interaction with
key enzymes in the vitamins D and C metabolism pathways (Fig 5C).
SARS-CoV-2 viral infection causesmetabolic perturbations of vitamin D
metabolism in the host resulting in disruptions in cellular homeo-
stasis. We propose support therapy management strategies where
vitaminD supplements are provided to all COVID-19 patients. Our results
also show that tryptophan, melatonin and prostaglandins, important
compounds for immunity andhomeostasis (Gitto et al, 2011; Platten et al,
2019), are affected by the infection of SARS-CoV-2 andwe provide insight
into the viral mechanism of action within the human body.
In summary, we have provided a platform for drug target pre-
diction against COVID-19, and future studies on viral entry inhibi-
tion, antioxidant therapy, and immune regulation.
Materials and Methods
For our modelling analyses, we based our reconstruction in the in-
tegrated macrophage cell with the SARS-CoV-2 virus model, previously
constructed by Renz et al (2020) to develop a new human airway
epithelial cell integrated with the SARS-CoV-2 virus. We predicted the
reactions which were critical for the survival of the virus in both cell
compartments (macrophage and epithelial cells); our results provide
insights into COVID-19 treatment management strategies.
GEM reconstruction, curation, and simulations
Weobtained an automated draft reconstruction of the human airway
epithelial cell (Wang et al, 2012) and evaluated the metabolic
functions and reactions collected in the draft reconstruction against
organism-specific literature. We used the gene expression datasets
of the human airway epithelial cell (Deprez et al, 2019 Preprint; Vieira
Braga et al, 2019) to curate, annotate and improve on the model (Fig
8). We manipulated and simulated the model, including the addition
of the gene expression data, with COBRApy (Ebrahim et al, 2013) and
GLPK (https://www.gnu.org/software/glpk/). We obtained additional
Figure 7. Pi-pathway intersection nodes - Nsp7 and Orf8a in carbohydrate and fatty acid metabolism.
(A) PPi-pathway intersection node—Nsp7. (B) PPi-Pathway intersection node—Orf8a. (C) PPi-pathway intersection node—Nsp7 and Orf8a.
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reactions, gene-to-reaction associations, and pathways (that were
not in the automated model) from HumanCyc (Trupp et al, 2010) to
develop a new genome-scale metabolic model (GEM) of the human
airway epithelial cell. We improved on the new reconstruction by
mapping the genes and reactions of the GEM to Recon3D, a standard
human metabolic model, MetaNetX 4.2, BiGG, ChEBI, MetaCyc, and
PubChem databases (Caspi et al, 2014; Hastings et al, 2016; Norsigian
et al, 2020; Moretti et al, 2021) and produced a revised human airway
epithelial cell iHsaEC21 (Fig 8). The revised model reconstruction,
iHsaEC21, can be instantiated without error on the COBRA software
(version 0.16.0) (Ebrahim et al, 2013).
Model optimisation
To improve on the quality of the model, we removed the reactions
with dead-end metabolites, which were previously found in the
automated model. This was followed by iteratively assessing the
model and accounting for the cell-specific metabolic and exchange
reactions in the epithelial cell model. We compared and performed
various iterations of the new GEM with Recon3D, MetaCyc, MetaNetX
4.2, BiGG, ChEBI, and PubChem databases (Caspi et al, 2014; Hastings
et al, 2016; Norsigian et al, 2020; Kim et al, 2021; Moretti et al, 2021). As
a result, we added charge and formulae to 1,473 compounds on the
new GEM. During the iterations and optimisation of the model, we
performed quality control checks on MEMOTE, a standardised genome-
scale metabolic model testing software (Leiven et al, 2020).
Integration of the human airway epithelial cell model and the
SARS-CoV-2 virus
We integrated the viral biomass maintenance function, previously de-
veloped for themacrophage cell (Renz et al. 2020, 2021) into thenewGEM
to produce an integrated model of iHsaEC21+SARS-CoV-2. We interro-
gated the new model to identify the host-dependency factors for the
SARS-CoV-2 virus by using the novel software tool findCPcli.
The new GEM is encoded in the Systems Biology Markup Lan-
guage (SBML) (Keating et al, 2020) (iHsaEC21); i for in silico, Hsa forH.
sapiens, and EC for airway epithelial cell published in 2021. iHsaEC21
consists of 3,752 reactions, 3,914 metabolites, 4,660 genes, and 48
metabolic pathways.
To assess and predict the performance of the models, we made
use of FBA and FVA (Orth et al, 2010). FBA is a computational method
that can be applied efficiently to genome-scale models to estimate
the fluxes of reactions at a steady state. It is based on the solution
of a linear programming problem that maximizes an objective
function of interest subject to a set of constraints on the fluxes of
the reactions. The linear programming problem associated with FBA
can be expressed as follows:
max c⋅v;
s:t: S⋅v = 0;
L ≤ v ≤ U;
where v is the vector of fluxes, c represents the objective function
coefficients, S is the stoichiometry matrix, and L and U are lower and
upper bounds on the fluxes. Thus, c v is the objective function, which
usually refers to the growth rate of the organism and S v = 0 represents
the balance of fluxes at steady state.
FVA is also based on the solution of linear programming
problems, and its main use is the computation of ranges of fluxes
that are compatible with given flux constraints. For instance, if the
growth rate predicted by FBA is μmax, then the range of fluxes of a
given reaction i that are compatible with such growth rate can be
Figure 8. Development of an integrated model of the
Human Airway Epithelial cell and SARS-CoV-2.
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obtained by minimizing andmaximizing the following programming
problem:
min=max vi;
s:t: S⋅v = 0;
L ≤ v ≤ U;
vgrowth = μmax;
where vgrowth is the flux of the reaction associated with growth and vi
is the flux of reaction i. FBA and FVA were computed on themetabolic
network of the host, bothwith andwithout the reactionmodelling the
production of the virus, by using the Python toolbox COBRApy.
Bottleneck reactions, like chokepoint reactions, are required for
the reaction synthesis and the removal of these reactions will cause
an accumulation or depletion of the metabolites; thus, they rep-
resent potential drug targets. The software tool findCPcli was de-
veloped to compute bottleneck reactions on genome-scale models
by considering the structural and dynamic information of the
models. The dynamic information is considered as follows: (a) FVA
is run to compute lower and upper flux bounds of the reactions; (b)
the obtained flux bounds are used to identify reversible and non-
reversible; and (c) this directionality of reactions is used to de-
termine consumer and producer reactions, and in turn, bottleneck
reactions. In addition to the computation of bottleneck reactions,
findCPcli can also compute and remove dead-end metabolites, find
essential reactions, and update the flux bounds of the reactions
according to the results of FVA.
Data Availability
Themodel has been deposited as an SBML Level 3 Version 1 (Hucka et al,
2018)filewith FBC extension and theminimal information required in the
annotation of models (MIRIAM) (Juty et al, 2012) in BioModels (https://
www.ebi.ac.uk/biomodels/MODEL2007210001) (Malik-Sheriff et al, 2020).
The source code of findCPcli together with its documentation is available
at https://github.com/findCP/findCPcli. The tool requires Python 3.5 (or
higher) and can be installed with pip, the standard package installer for
Python. The pathway maps were created with the pathway collage
software (Paley et al, 2016) and the essential reactions are available as a
smart table on HumanCyc (https://biocyc.org/group?id=biocyc17-29351-
3833343490).
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(2020) BiGG models 2020: Multi-strain genome-scale models and
expansion across the phylogenetic tree. Nucleic Acids Res 48:
D402–D406. doi:10.1093/nar/gkz1054
Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J (2020) Substantial
undocumented infection facilitates the rapid dissemination of novel
coronavirus (SARS-CoV2). Science 368: 489–493. doi:10.1126/
science.abb3221
Lieven C, Beber ME, Olivier BG, Bergmann FT, Ataman M, Babaei P, Bartell JA,
Blank LM, Chauhan S, Correia K, et al (2020) MEMOTE for standardized
genome-scale metabolic model testing. Nat Biotechnol 38: 272–276.
doi:10.1038/s41587-020-0446-y
Liu Y, Qu HQ, Qu J, Tian L, Hakonarson H (2020) Expression pattern of the
SARS-CoV-2 entry genes ACE2 and TMPRSS2 in the respiratory tract.
Viruses 12: 1174. doi:10.3390/v12101174
Malik-Sheriff RS, Glont M, Nguyen TVN, Tiwari K, Roberts MG, Xavier A, Vu MT,
Men J, Maire M, Kananathan S, et al (2020) BioModels-15 years of
sharing computational models in life science. Nucleic Acids Res 48:
D407–D415. doi:10.1093/nar/gkz1055
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P,
Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, et al (2017) Vitamin D
supplementation to prevent acute respiratory tract infections:
Systematic review and meta-analysis of individual participant data.
BMJ 356: i6583. doi:10.1136/bmj.i6583
Mazzon M, Marsh M (2019) Targeting viral entry as a strategy for broad-
spectrum antivirals. F1000Res 8: 1628. doi:10.12688/f1000research.
19694.1
Mitchell F (2020) Vitamin-D and COVID-19: Do deficient risk a poorer
outcome? Lancet Diabetes Endocrinol 8: 570. doi:10.1016/S2213-
8587(20)30183-2
Moretti S, Tran VDT, Mehl F, Ibberson M, Pagni M (2021) MetaNetX/MNXref:
Unified namespace for metabolites and biochemical reactions in the
context of metabolic models. Nucleic Acids Res 49: D570–D574.
doi:10.1093/nar/gkaa992
Müller C, Hardt M, Schwudke D, Neuman BW, Pleschka S, Ziebuhr J (2018)
Inhibition of cytosolic phospholipase A2α impairs an early step of
Integrated human/SARS-CoV-2 metabolic model Bannerman et al. https://doi.org/10.26508/lsa.202000954 vol 4 | no 10 | e202000954 12 of 13
coronavirus replication in cell culture. J Virol 92: e01463–17.
doi:10.1128/JVI.01463-17
Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA (1997)
Effect of disease modifying agents on the lipid profiles of patients
with rheumatoid arthritis. Ann Rheum Dis 56: 374–377. doi:10.1136/
ard.56.6.374
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Renz A, Widerspick L, Dräger A (2021) Genome-scale metabolic model of
infection with SARS-CoV-2 mutants confirms guanylate kinase as
robust potential antiviral target. Genes (Basel) 12: 796. doi:10.3390/
genes12060796
Seaver SMD, Liu F, Zhang Q, Jeffryes J, Faria JP, Edirisinghe JN, Mundy M, Chia N,
Noor E, Beber ME, et al (2021) The ModelSEED Biochemistry Database
for the integration of metabolic annotations and the reconstruction,
comparison and analysis of metabolic models for plants, fungi and
microbes. Nucleic Acids Res 49: D575–D588. doi:10.1093/nar/gkaa1143
Steward J (2020) Host pathways in coronavirus replication and COVID-19
pre-clinical drug target identification using proteomic




Trupp M, Altman T, Fulcher CA, Caspi R, Krummenacker M, Paley S, Karp PD
(2010) Beyond the genome (BTG) is a (PGDB) pathway genome
database: HumanCyc. Genome Biol 11: O12. doi:10.1186/gb-2010-11-
s1-o12
Uzun T, Toptas O (2020) Artesunate: Could be an alternative drug to
chloroquine in COVID-19 treatment? Chin Med 15: 54. doi:10.1186/
s13020-020-00336-8
Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, Brouwer S,
Gomes T, Hesse L, Jiang J, et al (2019) A cellular census of human lungs
identifies novel cell states in health and in asthma. Nat Med 25:
1153–1163. doi:10.1038/s41591-019-0468-5
Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (2008) SARS
coronavirus entry into host cells through a novel clathrin- and
caveolae-independent endocytic pathway. Cell Res 18: 290–301.
doi:10.1038/cr.2008.15
Wang Y, Eddy JA, Price ND (2012) Reconstruction of genome-scale metabolic
models for 126 human tissues using mCADRE. BMC Syst Biol 6: 153.
doi:10.1186/1752-0509-6-153
Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, Sajed T,
Johnson D, Li C, Karu N, et al (2018) HMDB 4.0: The humanmetabolome
database for 2018. Nucleic Acids Res 46: D608–D617. doi:10.1093/nar/
gkx1089
Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB (2004) Computational
analysis of plasmodium falciparum metabolism: Organizing genomic
information to facilitate drug discovery. Genome Res 14: 917–924.
doi:10.1101/gr.2050304
Zhong J, Tang J, Ye C, Dong L (2020) The immunology of COVID-19: Is immune
modulation an option for treatment? Lancet Rheumatol 2: e428–e436.
doi:10.1016/S2665-9913(20)30120-X
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, ZhangW, Si HR, Zhu Y, Li B, Huang CL,
et al (2020) A pneumonia outbreak associated with a new coronavirus
of probable bat origin. Nature 579: 270–273. doi:10.1038/s41586-020-
2012-7
License: This article is available under a Creative
Commons License (Attribution 4.0 International, as
described at https://creativecommons.org/
licenses/by/4.0/).
Integrated human/SARS-CoV-2 metabolic model Bannerman et al. https://doi.org/10.26508/lsa.202000954 vol 4 | no 10 | e202000954 13 of 13
